Drag a card by its title · ⚙ to size, swap or remove

Who

John A. Orwin

Director

Company insider

Files Form 4 as: Director, First Tracks Biotherapeutics; Director, AnaptysBio; Director, Travere Therapeutics; Director, CARGO Therapeutics; President & CEO, Atreca; Director, Seagen; Director, Array Biopharma; President & CEO, Relypsa.

Every Form 4 they filed

In numbers

Trades disclosed: 285
Buys: 4
Sells: 23
Bought: $298K
Sold: $8.6M
Companies: 10
Companies where not an officer: 7
First trade: 19 Nov 2009
Last trade: 15 Sep 2026
Last filed: 17 Sep 2026

Companies traded

Where they are an officer

AtrecaDirector, Officer · last 11 Apr 20242 buys · 2 sells

RelypsaDirector, Officer · last 1 Sep 20161 buy · 8 sells

AffymaxDirector, Officer · last 28 Jun 20130 buys · 13 sells

Everywhere else they filed: board seats, 10% stakes, other companies

ANAB AnaptysBioDirector · Biotechnology · last 15 Sep 20260 buys · 0 sells

TRAX First Tracks BiotherapeuticsDirector · Biotechnology · last 15 Sep 20260 buys · 0 sells

TVTX Travere TherapeuticsDirector · Biotechnology · last 19 May 20260 buys · 0 sells

CARGO TherapeuticsDirector · last 19 Aug 20250 buys · 0 sells

SeagenDirector · last 14 Dec 20231 buy · 0 sells

Array BiopharmaDirector · last 30 Jul 20190 buys · 0 sells

NeurogesXDirector · last 7 Jun 20120 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026

Buys above the line, sells below, each month.

Every trade

Traded	Company	What	Amount
15 Sep 2026filed 17 Sep 2026	TRAX First Tracks BiotherapeuticsBiotechnology	SEC FORM 4 Code M	—1,300 at $0.00	filing
15 Sep 2026filed 17 Sep 2026	TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology	SEC FORM 4 Code M	—1,300 at $0.00	filing
15 Sep 2026filed 17 Sep 2026	TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology	SEC FORM 4 Code M	—1,300 at $0.00	filing
15 Sep 2026filed 17 Sep 2026	TRAX First Tracks BiotherapeuticsBiotechnology	SEC FORM 4 Code M	—1,300 at $0.00	filing
15 Sep 2026filed 17 Sep 2026	ANAB AnaptysBioBiotechnology	SEC FORM 4 Code M	—1,300 at $0.00	filing
15 Sep 2026filed 17 Sep 2026	ANAB AnaptysBiooption or derivative · Biotechnology	SEC FORM 4 Code M	—1,300 at $0.00	filing
15 Sep 2026filed 17 Sep 2026	ANAB AnaptysBiooption or derivative · Biotechnology	SEC FORM 4 Code M	—1,300 at $0.00	filing
15 Sep 2026filed 17 Sep 2026	ANAB AnaptysBioBiotechnology	SEC FORM 4 Code M	—1,300 at $0.00	filing
15 Jun 2026filed 17 Jun 2026	ANAB AnaptysBioBiotechnology	SEC FORM 4 Code M	—6,030 at $0.00	filing
15 Jun 2026filed 17 Jun 2026	ANAB AnaptysBiooption or derivative · Biotechnology	SEC FORM 4 Code M	—6,030 at $0.00	filing
15 Jun 2026filed 17 Jun 2026	ANAB AnaptysBiooption or derivative · Biotechnology	SEC FORM 4 Code M	—6,030 at $0.00	filing
15 Jun 2026filed 17 Jun 2026	ANAB AnaptysBioBiotechnology	SEC FORM 4 Code M	—6,030 at $0.00	filing
15 Jun 2026filed 17 Jun 2026	TRAX First Tracks BiotherapeuticsBiotechnology	SEC FORM 4 Code M	—6,030 at $0.00	filing
15 Jun 2026filed 17 Jun 2026	TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology	SEC FORM 4 Code M	—6,030 at $0.00	filing
15 Jun 2026filed 17 Jun 2026	TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology	SEC FORM 4 Code M	—6,030 at $0.00	filing
15 Jun 2026filed 17 Jun 2026	TRAX First Tracks BiotherapeuticsBiotechnology	SEC FORM 4 Code M	—6,030 at $0.00	filing
19 May 2026filed 21 May 2026	TVTX Travere TherapeuticsBiotechnology	SEC FORM 4 Code A	—4,000 at $0.00	filing
19 May 2026filed 21 May 2026	TVTX Travere Therapeuticsoption or derivative · Biotechnology	SEC FORM 4 Code A	—12,000 at $0.00	filing
19 May 2026filed 21 May 2026	TVTX Travere Therapeuticsoption or derivative · Biotechnology	SEC FORM 4 Code A	—12,000 at $0.00	filing
19 May 2026filed 21 May 2026	TVTX Travere TherapeuticsBiotechnology	SEC FORM 4 Code A	—4,000 at $0.00	filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed27

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.